Laurus Labs Reports Strong Q2 FY27 Results and Expands CDMO Capabilities
Laurus Labs Ltd · Press Release · 29 Oct 2026, 9:06 pm
Laurus Labs Reports Strong Q2 FY27 Results and Expands CDMO Capabilities Laurus Labs reported strong Q2 FY27 financial results on 29th Oct'26, with revenue increasing 33% YoY to ₹2,206 Cr and net profit surging 126% YoY to ₹441 Cr. EBITDA rose 78% YoY to ₹762 Cr, with margins expanding 850 bps to 34.5%, driven by 75% YoY growth in the CDMO segment to ₹904 Cr. The company declared an interim dividend of ₹1.00 per share. Additionally, Laurus signed definitive agreements to acquire a 60% stake in Galenvs Sciences and 52% in SI &C Resins to enhance its oligonucleotide and peptide CDMO capabilities.
Original exchange filing (PDF)
More announcements from Laurus Labs Ltd
- Please see annexed enclosure. · 18 Nov 2026
- Please see annexed enclosure. · 11 Nov 2026
- Please see annexed enclosure. · 03 Nov 2026
- Please see enclosed annexure. · 30 Oct 2026
- Please see enclosed annexure · 29 Oct 2026
- Please see enclosed annexure · 29 Oct 2026
- Appointment of Mr. Kundan Kumar Jha as Joint Company Secretary of the Company w.e.f. November 1, 2026 · 29 Oct 2026
- Please see enclosed annexure · 29 Oct 2026
